ProKidney to Participate in the UBS Virtual Organ Restoration Day
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ProKidney Corp. (Nasdaq: PROK), a late clinical-stage biotech company focusing on developing a first-in-class cell therapy for chronic kidney disease (CKD), has announced its participation in the UBS Virtual Organ Restoration Day on October 15, 2024. Senior management team members will engage in a fireside chat at 9:00am ET.
The event will be accessible via a live webcast, with a link provided for public viewing. Additionally, the webcast will be available through ProKidney's website in the 'Events' section of the Investor Relations tab. A replay will remain accessible for 90 days following the event.
ProKidney's management team will also conduct one-on-one meetings with investors during the event. Interested parties are advised to contact their UBS representative to arrange these meetings.
Details
News Market Reaction – PROK
The recorded move for PROK in the trading session of this news was -1.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the UBS Virtual Organ Restoration Day, which will be taking place on October 15, 2024.
| UBS Virtual Organ Restoration Day | ||
| Date: | Tuesday, October 15, 2024 | |
| Time: | 9:00am ET | |
| Format: | Fireside Chat | |
| Webcast Link: | https://kvgo.com/ubs/prokidney-oct-2024 | |
The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the fireside chat, a replay of the webcast will be available for 90 days.
The ProKidney management team will also host one-on-one meetings during this event. Interested investors should contact their UBS representative to schedule meetings.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.